Company Filing History:
1 out of 25 
1 out of 168 
1 out of 321 
Years Active: 2016
Title: Innovator Dong Jin Jeong: Advancements in Vaccine Adjuvants
Introduction: Dong Jin Jeong is a prominent inventor based in Daejeon, South Korea, recognized for his significant contributions to the field of vaccine development. With a focus on enhancing vaccine efficacy, Jeong has been at the forefront of pioneering innovations that aim to prevent and treat diseases.
Latest Patents: Jeong holds a notable patent for his invention titled "Adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles." This invention revolves around a new adjuvant composition that utilizes nanoparticles made through ionic bonding between poly-gamma-glutamic acid, known for its safety, and chitosan. The patent describes a vaccine composition that incorporates these poly-gamma-glutamic acid-chitosan nanoparticles along with an antigen. The primary advantage of this adjuvant is its minimal toxicity and side effects, making it a valuable addition to vaccines designed for human or animal use, particularly against viral, bacterial infections, and cancers. This innovation is key to enhancing the production of antibodies, thereby improving vaccine responses.
Career Highlights: Throughout his career, Jeong has engaged with leading organizations that focus on research and development in biotechnology and pharmaceuticals. Notably, he has made significant contributions while working at Bioleaders Corporation and Kookmin University Industry Academy Cooperation Foundation, where his expertise in vaccine technology has been instrumental.
Collaborations: Jeong has worked alongside esteemed colleagues in his field, including Moon-Hee Sung and Haryoung Poo. Their collaborative efforts have driven advancements in the development and application of innovative solutions in vaccine technology.
Conclusion: Dong Jin Jeong's inventive work, particularly in the realm of vaccine adjuvants, has showcased his commitment to enhancing human and animal health. His patent on poly-gamma-glutamic acid-chitosan nanoparticles demonstrates a significant step forward in vaccine enhancement, which could have lasting impacts on public health and disease prevention.